Panretin is a naturally-occurring retinoid related to vitamin A that activates processes which regulate cell differentiation and proliferation. It has been shown to inhibit the growth of Kaposi’s sarcoma cells in vitro.

Authorization: for topical treatment of cutaneous Kaposi’s sarcoma lesions who do not qualify for systemic treatment (e.g. no visceral/pulmonary involvement; no >10 new cutaneous lesions in the past month), for treatment of severe chronic hand eczema refractory to topical corticosteroids.

Dosing: apply two times a day, gradually increasing to four times a day if necessary; avoid normal skin

PRECAUTIONS: photosensitivity; irritation to normal skin; extreme reaction of the lesions (pain, exfoliation, paresthesias)

DRUG INTERACTIONS: concomitant use of DEET-containing preparations
REFERENCES


Revision History:

Date Reviewed/No Updates: 01.13.15 by C. Sanders, MD
Date Approved by P&T Committee: 01.27.15
Date Reviewed/No Updates: 01.26.16 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 01.26.16
Date Reviewed/No Updates: 01.24.17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 01.24.17

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/24/17</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>